Stuart Alexandra, Baker Amanda L, Bowman Jenny, McCarter Kristen, Denham Alexandra Mary Janice, Lee Nicole, Colyvas Kim, Dunlop Adrian
School of Psychology, Faculty of Science, University of Newcastle, Callaghan, New South Wales, Australia.
School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia.
BMJ Open. 2017 Sep 7;7(9):e015383. doi: 10.1136/bmjopen-2016-015383.
People who use methamphetamine (MA) regularly, often experience symptoms of mental ill health associated with the use of the drug. These include symptoms of psychosis, depression, anxiety and also cognitive deficits. Accordingly, psychological treatments aim to reduce MA use and related problems, including symptoms of mental ill health. Although there has been a substantial body of research reporting on the evidence of effectiveness of psychological treatments for MA use, there is a paucity of research addressing the effectiveness of these treatments for coexisting symptoms of mental ill health. We aim to address this gap by providing a comprehensive overview of the evidence for psychological treatments for MA use and associated symptoms of mental ill health in experimental/controlled clinical studies. In addition, a critical evaluation of study methods and the outcomes of psychological interventions on MA use and symptoms of mental ill health will be conducted.
The Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement will be used to inform the methods of this review. Eight electronic peer-reviewed databases will be searched. Pilot searches have been conducted for MA literature considering controlled clinical trials only. Eligible articles will be independently assessed against inclusion criteria. Before final analyses are completed, searches will be rerun and if eligible, additional studies will be retrieved for inclusion. A quantitative synthesis of the findings will be reported where possible, and 'summary of findings' tables will be generated for each comparison. Risk ratios and 95% CI (dichotomous outcomes) will be calculated and/or effect size according to Cohen's formula (continuous outcomes) for the primary outcome of each trial.
No ethical issues are foreseen. Findings will be disseminated widely to clinicians and researchers via journal publication and conference presentation(s).
CRD42016043657.
经常使用甲基苯丙胺（MA）的人常常会出现与药物使用相关的心理健康问题症状。这些症状包括精神病、抑郁、焦虑症状以及认知缺陷。因此，心理治疗旨在减少MA的使用及相关问题，包括心理健康问题症状。尽管已有大量研究报告了心理治疗对MA使用的有效性证据，但针对这些治疗对并存的心理健康问题症状的有效性的研究却很少。我们旨在通过全面概述实验性/对照临床研究中针对MA使用及相关心理健康问题症状的心理治疗证据来填补这一空白。此外，还将对研究方法以及心理干预对MA使用和心理健康问题症状的结果进行批判性评估。
将使用《Cochrane干预措施系统评价手册》和《系统评价与Meta分析优先报告项目声明》来指导本综述的方法。将检索八个电子同行评审数据库。仅考虑对照临床试验对MA文献进行了预检索。符合条件的文章将根据纳入标准进行独立评估。在完成最终分析之前，将重新进行检索，如果符合条件，将检索其他研究纳入。将尽可能报告研究结果的定量综合，并为每个比较生成“结果总结”表。将根据每个试验的主要结果，计算风险比和95%置信区间（二分结果），并根据科恩公式计算效应量（连续结果）。
预计不存在伦理问题。研究结果将通过期刊发表和会议报告广泛传播给临床医生和研究人员。
CRD42016043657。
